Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150262 | 0.86 | FLT3 (0.50) | FLT3CA12CA1CA2CA7 | |
| SCHEMBL124810 | 0.83 | FLT3 (0.53) | FLT3CA12CA1CA2CA7 | |
| SCHEMBL10157278 | 0.78 | FLT3 (0.52) | FLT3CA12CA1CA2CA7 | |
| SCHEMBL13384225 | 0.74 | FLT3 (0.62) | FLT3ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL10848792 | 0.73 | FLT3 (0.64) | FLT3ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL14236452 | 0.73 | FLT3 (0.53) | FLT3CA12CA1CA2CA7 | |
| SCHEMBL147014 | 0.73 | TRPV4 (0.43) | FLT3ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3340189 | 0.73 | ALDH1A1 (0.65) | FLT3ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL9067995 | 0.72 | FLT3 (0.56) | FLT3CA12CA1CA2CA7 | |
| SCHEMBL3954097 | 0.72 | ALDH1A1 (0.58) | FLT3CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921349-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | CTSS, DNPEP, PEPD | FLT3 2316/4885CA12 483/4885CA1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.